Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer

BACKGROUND AND PURPOSE: Esophageal cancer has a persistently low 5-year survival rate and has recently been classified as a cancer of unmet need by Cancer Research UK. Consequently, new approaches to therapy are urgently required. Here, we tested the hypothesis that an ATR inhibitor, VX-970, used in...

Descripción completa

Detalles Bibliográficos
Autores principales: Leszczynska, Katarzyna B., Dobrynin, Greg, Leslie, Rhea E., Ient, Jonathan, Boumelha, Adam J., Senra, Joana M., Hawkins, Maria A., Maughan, Tim, Mukherjee, Somnath, Hammond, Ester M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Scientific Publishers 2016
Materias:
Experimental Radiotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154234/
https://www.ncbi.nlm.nih.gov/pubmed/27839769
http://dx.doi.org/10.1016/j.radonc.2016.10.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154234/
https://www.ncbi.nlm.nih.gov/pubmed/27839769
http://dx.doi.org/10.1016/j.radonc.2016.10.023

Ejemplares similares